LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis

In recent years, growing evidences have demonstrated promising synergistic antitumor effects of radiotherapy combined with immunotherapy. More over, LDRT may enhance the antitumor effect of immunotherapy by altering the tumor immune microenvironment (TIME) and adjusting the immune response. In this study, we will explore the safety and feasibility of LDRT and immunochemotherapy in liver metastatic colorectal cancer. 9-18 participants will be enrolled in this study. All will take part at Daping Hospital, Army Medical University.

Trial Details

NCT ID
NCT06848465
Phase
PHASE1
Sponsor
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Low Dose Radiotherapy
  • Short course Radiotherapy
  • XELOX
  • Tislelizumab
Locations (sample)
  • Chongqing, Chongqing Municipality, China|29.56026,106.55771
  • Chongqing, Chongqing Municipality, China|29.56026,106.55771

Key Eligibility Criteria

  • Age between18 and 75 years old.
  • Histopathological confirmed MSS/pMMR adenocarcinoma of the colon or rectum.
  • The clinical baseline stage of rectal cancer assessed by MRI/CT/Transrectal ultrasound was T3-4Nx or TXN1-2.
  • Simultaneous liver metastasis confirmed by imaging examination.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →